85. Idiopathic interstitial pneumonia
514 clinical trials,   377 drugs   (DrugBank: 108 drugs),   97 drug target genes,   204 drug target pathways

Searched query = "Idiopathic interstitial pneumonia", "IIPs", "Idiopathic pulmonary fibrosis", "IPF", "Usual interstitial pneumonia", "UIP", "Non-specific interstitial pneumonia", "NSIP", "Acute interstitial pneumonia", "AIP", "Diffuse alveolar damage", "DAD", "COP", "Organizing pneumonia", "OP", "Desquamative interstitial pneumonia", "DIP", "Respiratory bronchiolitis - associated interstitial lung disease", "RB-ILD", "Lymphocytic interstitial pneumonia", "LIP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
7 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2004-001261-17-IE
(EUCTR)
28/01/200508/12/2004An Open-Label Study of the Safety of Subcutaneous Recombinant Interferon gamma-1b in Patients with Idiopathic Pulmonary FibrosisAn Open-Label Study of the Safety of Subcutaneous Recombinant Interferon gamma-1b in Patients with Idiopathic Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis (IPF)Trade Name: Immukin
Product Name: Interferon gamma-1b
InterMuneNULLNot RecruitingFemale: yes
Male: yes
Phase 3Ireland
2EUCTR2004-000029-31-IE
(EUCTR)
28/01/200508/12/2004A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Interferon gamma-Ib in patients with Idiopathic Pulmonary Fibrosis The INSPIRE Trial - International Study of Survival outcomes in IPF with Interferon gamma-1b) - INSPIREA Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Interferon gamma-Ib in patients with Idiopathic Pulmonary Fibrosis The INSPIRE Trial - International Study of Survival outcomes in IPF with Interferon gamma-1b) - INSPIRE Idiopathic Pulmonary Fibrosis (IPF)Trade Name: Immukin
Product Name: Interferon gamma-1b
InterMuneNULLNot RecruitingFemale: yes
Male: yes
600Phase 3Ireland
3NCT00075998
(ClinicalTrials.gov)
December 200312/1/2004The INSPIRE Trial: A Study of Interferon Gamma-1b for Idiopathic Pulmonary Fibrosis (IPF)A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (The INSPIRE Trial)Idiopathic Pulmonary Fibrosis;Lung Disease;Pulmonary FibrosisDrug: Interferon gamma-1b (Actimmune)InterMuneNULLTerminated40 Years79 YearsBoth826Phase 3United States
4NCT00076635
(ClinicalTrials.gov)
November 200328/1/2004An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPFAn Open-Label Study of the Safety of Subcutaneous Recombinant Interferon Gamma-1b in Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosis;Pulmonary Fibrosis;Lung DiseaseDrug: Interferon gamma-1bInterMuneNULLTerminatedN/AN/ABoth91Phase 3United States
5NCT00052052
(ClinicalTrials.gov)
September 200221/1/2003An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis.Lung Disease;Pulmonary FibrosisDrug: interferon-gamma 1bInterMuneNULLCompleted20 Years79 YearsBoth210Phase 2United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00052039
(ClinicalTrials.gov)
April 200221/1/2003A Randomized, Double-Blind, Three-Arm, Phase 3b Study Comparing the Safety and Efficacy of Interferon Gamma-1b With Azathioprine, and Azathioprine Alone in Patients With IPF Receiving PrednisoneA Randomized, Double-Blind, Three-Arm, Phase IIIb Study Comparing the Safety and Efficacy of Interferon Gamma-1b Alone, IFN-Gamma 1b With Azathioprine, and Azathioprine Alone in Patients With Idiopathic Pulmonary Fibrosis Receiving PrednisoneLung Disease;Pulmonary FibrosisDrug: interferon-gamma 1b;Drug: azathioprineInterMuneNULLTerminated20 Years79 YearsBoth0Phase 3Italy
7NCT00047658
(ClinicalTrials.gov)
November 20019/10/2002A Study of the Safety and Clinical Effects of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Biology, and Clinical Effects of Interferon Gamma-1b Administered Subcutaneously to Patients With IPF Followed by an Open-Label ExtensionIdiopathic Pulmonary FibrosisDrug: Interferon-gamma 1bInterMuneNULLCompleted20 Years79 YearsBoth32Phase 2United States